Is PharmaCyte Biotech, Inc. overvalued or undervalued?

As of 3 October 2023, PharmaCyte Biotech, Inc. has moved from fair to overvalued. The company currently exhibits a price-to-earnings ratio of 45.2, a price-to-book ratio of 5.6, and a debt-to-equity ratio of 0.1, which indicates a relatively high valuation compared to its earnings and assets. When compared to peers such as Amgen Inc. with a P/E ratio of 22.5 and Gilead Sciences, Inc. at 11.8, PharmaCyte's valuation appears excessive.
Overall, the analysis suggests that PharmaCyte Biotech is overvalued given its high ratios in relation to industry standards. This valuation is further supported by the company's recent stock performance, which has lagged behind the Sensex, reinforcing the notion that the current market price may not accurately reflect its underlying value.